RENBP and diabetes mellitus: Blockage of the crosstalk between the thrombin-PAR-1 system and the AGE-RAGE axis by rivaroxaban may be a new therapeutic option to reduce thromboembolic events such as infrainguinal graft occlusion in patients with diabetes [48].